Roche Again Delays $4.3B Spark Buy Amid Regulatory Review
Law360 (May 14, 2019, 2:19 PM EDT) -- Roche and gene therapy company Spark Therapeutics said Tuesday that they are once again pushing back their $4.3 billion merger, electing to refile with U.S. antitrust regulators to allow more time for the government to complete its review.
Swiss pharmaceutical company F. Hoffmann-La Roche AG and Spark Therapeutics Inc. said the companies plan to withdraw and refile their premerger notification form with the U.S. Department of Justice and Federal Trade Commission in accordance with the Hart-Scott-Rodino Act on May 23.
The companies said the decision to refile will extend the waiting period to June 7, unless the government grants early termination of...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!